🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to share we've been named a Bay Area Top Workplace for the 4th year in a row! This honor is a testament to our amazing team and the vibrant, inclusive culture we've built. Thank you, #TeamAdverum! Here’s to more pioneering, collaboration, and excellence!

Join us in welcoming Jason Mitchell as our new Chief Commercial Officer! With 20+ years of leadership experience, including leading a top #retinaldisease launch, Jason will be invaluable as we prepare for our pivotal program in #wetAMD. Learn more: bit.ly/3YmUonT

Last week, we presented at Ophthalmology's #Eyecelerator, sharing data on Ixo-vec, our #GTx product candidate for #wetAMD. We’re honored to contribute to groundbreaking efforts in ophthalmology and strive to set a new standard of care. Tune in for 52-week LUNA data & Phase 3

Today, Adverum Biotechnologies reported our third quarter financial results and updated anticipated milestones. Read here for more details: bit.ly/4fxolaq

Today, Team Adverum had the opportunity to volunteer with Samaritan House, helping prepare and distribute food for community members in need. As Adverians, we aim to make this world a better place, whether it’s helping to address food insecurity in our community or working to

Yesterday, we announced that on Monday, November 18th we’ll be sharing 52-week data from our Phase 2 LUNA trial, 4-year data from our OPTIC trial and key design elements from our upcoming Phase 3 pivotal trial. Join our webcast Monday morning to learn more. Learn more here:

We are thrilled to announce positive 52-week LUNA Phase 2 data and 4-year OPTIC clinical data that continue to establish Ixo-vec as a transformative and potential best-in-class therapy, potentially providing patients who have wet AMD with life-long benefit and a predictable

Later this week our team is headed to the #FLORetina in Florence, Italy, where we’ll present 52-week data from our LUNA Phase 2 trial of Ixo-vec. Ixo-vec is our single-injection #genetherapy candidate for treatment of patients with #wetAMD. Learn more: bit.ly/3UTE24c

February has already been a busy month for Adverum! We attended key ophthalmology meetings, including Angiogenesis, Vail Vitrectomy, Telluride Retina Film Festival, and Macula Society—engaging with colleagues, sharing updates, and gaining valuable insights. #GeneTherapy #wetAMD

Congratulations to Dr. Arshad Khanani on being awarded the Lawrence Singerman Medal by the Macula Society for “outstanding contributions to the advancement of science through retinal clinical trials.” Truly well-deserved recognition!

Adverum will be presenting at the 45th Annual TD Cowen Healthcare Conference Tuesday, March 4, at 11:50 a.m. ET. Watch live: bit.ly/4ewOCWq A replay will be available for at least 30 days.

Don’t miss our Board Director, Dr. Szilard Kiss at ARDS 2025! He’ll be presenting Advances in Ocular Gene Therapy for Inherited and Multifactorial Retinal Disorders on March 3 at 5:10 PM MT. See you there!

Adverum has initiated ARTEMIS, our Phase 3 trial of Ixo-vec for wet AMD—the first-ever registrational intravitreal gene therapy trial for this patient population. A huge milestone in advancing treatment. Kudos to our team for making it happen! 🔗 bit.ly/41pSFyj

Don’t miss the fireside chat with Adverum’s management team today at the Cowen 45th Annual Healthcare Conference at 11:50 AM EST. Watch live: bit.ly/4iq22VB The replay will be available for 30+ days. #CowenConference #genetherapy #wAMD

We had a great time at ARDS ‘25! Thanks to Dr. Don D’Amico, Dr. R.V. Paul Chan, and Dr. Tim Murray for another outstanding event, and to Dr. Szilárd Kiss for his presentation on Advances in Ocular Gene Therapy for Inherited Retinal Disorders. Special thanks to Medical

This #InternationalWomensDay, we’re celebrating the women of Adverum who are shaping the future of biotech—leading in gene therapy, mentorship & innovation. Swipe to see their insights on leadership & empowering women in STEM. #IWD2025 #AccelerateAction #DiversityInSTEM

Adverum is heading to the 2025 ASRS Business of Retina Meeting in Atlanta, GA, from March 28–30. We are looking forward to engaging discussions on what retina practices experience every day and learning more about how gene therapy can fit in.

It’s been a busy and insightful month for our team at Adverum attending key ophthalmology meetings! Grateful for the opportunity to learn about the latest innovations, connect with colleagues, and share updates on Ixo-vec and advancements in #genetherapy for #wetAMD.

Today Adverum participated in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference. Watch the webcast replay at: bit.ly/3C5hzaz

Adverum is in Seville, Spain, for the 16th Annual COPHy Congress on Controversies in Ophthalmology, taking place April 4-5. We believe in the power of collaboration to drive progress for patients, and we look forward to connecting with fellow leaders at the forefront of